P8IP
RARE icon

Pier 88 Investment Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pier 88 Investment Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,170
Closed -$426K – 124
2025
Q3 		$426K Sell
14,170
-560
-4% -$16.8K 0.08% 99
2025
Q2 		$536K Sell
14,730
-7,640
-34% -$275K 0.1% 85
2025
Q1 		$810K Buy
22,370
+8,280
+59% +$344K 0.16% 64
2024
Q4 		$593K Sell
14,090
-8,450
-37% -$419K 0.12% 68
2024
Q3 		$1.25M Sell
22,540
-3,430
-13% -$175K 0.28% 47
2024
Q2 		$1.07M Buy
25,970
+10,700
+70% +$457K 0.24% 57
2024
Q1 		$713K Sell
15,270
-5,320
-26% -$251K 0.18% 50
2023
Q4 		$985K Buy
20,590
+8,910
+76% +$345K 0.25% 52
2023
Q3 		$416K Sell
11,680
-11,620
-50% -$460K 0.1% 79
2023
Q2 		$1.07M Buy
23,300
+1,550
+7% +$71.9K 0.27% 61
2023
Q1 		$872K Hold
21,750
– – 0.21% 58
2022
Q4 		$1.01M Sell
21,750
-1,090
-5% -$42.9K 0.24% 53
2022
Q3 		$946K Buy
22,840
+7,290
+47% +$375K 0.22% 65
2022
Q2 		$928K Hold
15,550
– – 0.22% 71
2022
Q1 		$1.13M Hold
15,550
– – 0.4% 52
2021
Q4 		$1.31M Buy
15,550
+3,460
+29% +$282K 0.28% 67
2021
Q3 		$1.09M Buy
12,090
+5,025
+71% +$454K 0.33% 66
2021
Q2 		$673K Buy
7,065
+1,300
+23% +$135K 0.19% 90
2021
Q1 		$656K Buy
5,765
+2,445
+74% +$333K 0.22% 81
2020
Q4 		$459K Sell
3,320
-8,130
-71% -$964K 0.15% 100
2020
Q3 		$941K Sell
11,450
-5,065
-31% -$420K 0.29% 73
2020
Q2 		$1.29M Buy
16,515
+1,850
+13% +$122K 0.37% 68
2020
Q1 		$652K Hold
14,665
– – 0.24% 66
2019
Q4 		$626K Buy
14,665
+1,740
+13% +$71.8K 0.25% 55
2019
Q3 		$553K Buy
12,925
+2,560
+25% +$139K 0.21% 69
2019
Q2 		$658K Hold
10,365
– – 0.28% 61
2019
Q1 		$719K Buy
10,365
+3,050
+42% +$174K 0.33% 56
2018
Q4 		$318K Buy
7,315
+270
+4% +$14.8K 0.16% 67
2018
Q3 		$538K Buy
7,045
+1,245
+21% +$101K 0.23% 60
2018
Q2 		$446K Buy
+5,800
New +$375K 0.21% 64

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pier 88 Investment Partners's RARE Position: Q4 2025 in Review

Pier 88 Investment Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 14,170 shares — an estimated $426K sold.

Pier 88 Investment Partners first reported a position in RARE in Q2 2018 and held it in 30 quarters. The position peaked at $1.31M in Q4 2021. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Pier 88 Investment Partners reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Pier 88 Investment Partners sold 14,170 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $426K.
  • Pier 88 Investment Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 30 quarters.
  • Pier 88 Investment Partners's Ultragenyx Pharmaceutical position peaked at $1.31M in Q4 2021.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Pier 88 Investment Partners's 13F filing for Q4 2025, filed 4 Feb 2026.